Subcutaneous Immunoglobulin for Myasthenia Gravis

Phase

Condition

Neuropathy

Polymyositis (Inflammatory Muscle Disease)

Sarcopenia

Treatment

subcutaneous immunoglobulin (SCIG)

intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)

Clinical Study ID

NCT04728425

19-5378.2

Ages 18-100
All Genders

Study Summary

This is a prospective open-label, randomized, parallel arm clinical trial.

The primary objective of the study is to evaluate the safety and efficacy of Cuvitru 20% subcutaneous immunoglobulin in patients with myasthenia gravis (MG). The secondary objective is to evaluate patient preferences and effects on quality of life when treating MG patients with SCIG. Exploratory objectives are to compare de novo administration starting SCIG directly with those starting with a loading dose of IVIG followed by SCIG administration.

Patients over age 18 with moderate to severe MG with MGFA Class II-IV without contraindications to immunoglobulin will be considered for the study.

All patients will be eligible to enter either arm of the study, Arm 1: 10% Gammagard IVIG followed by 20% Cuvitry SCIG and Arm 2: Cuvitru 20% SCIG alone.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients over age 18
Patients with a confirmed diagnosis of myasthenia gravis based on clinical criteriaincluding fatiguable weakness and supported by either serological (acetylcholinereceptor, muscle specific kinase or anti-low-density lipoprotein receptor- relatedprotein 4 antibodies or electrophysiological testing (repetitive nerve stimulationof single fiber electromyography)
Myasthenia Gravis Federation of America class II-IV
Moderate to severe myasthenia gravis as defined by a quantitative myasthenia gravisscore >10 or generalized myasthenia gravis impairment index score > 11
Patient able to give consent and is able and willing to complete all studyprocedures and activities

Exclusion

Exclusion Criteria:

Patients who are pregnant or breastfeeding
Patients not able to complete the study procedures or with an alternate diagnosis
Patients with recent thymectomy in the past 6 months
Patients receiving another biologic agent such as rituximab, belimubab,cyclophosphamide and eculizumab in the past 6 months prior to study entry
No IVIG or subcutaneous immunoglobulin within the past month
Patients on prednisone who have had alterations in prednisone dose over the pastmonth prior to study entry
Patients will previous known allergy or severe adverse reaction to intravenous orsubcutaneous immunoglobulin
Evidence of renal insufficiency (Cr>1.5 x elevated) or liver disease (transaminases > 2.5 x elevation) at screening.

Study Design

subcutaneous immunoglobulin (SCIG)

August 28, 2020

December 30, 2023

Study Description

Myasthenia gravis (MG) is an autoimmune neuromuscular condition which can cause fatigable weakness of skeletal muscles including bulbar, ocular, limb, axial and respiratory muscles. Symptoms range from mild, transient double vision and ptosis to severe, life threatening diffuse weakness, and treatments which are immunosuppressive or immunomodulatory have been shown to improve outcome in MG. This includes 10% intravenous immunoglobulin (IVIG), which has previous been shown by our group to improve strength at 2 and 4 weeks in patients with MG. Due to delay in the onset of many immunosuppressives and potential side effects from steroids and other immunosuppressive medications, IVIG is also used in clinical practice as bridging of maintenance therapy until other therapies take effect or the patient stabilizes. In addition, there have been other studies suggesting that 20% subcutaneous immunoglobuin (SCIG) can be helpful to improve strength in patients with MG over a relatively short period of time (6 weeks). Some of these studies are ongoing and are further evaluating the ability of IVIG and SCIG to stabilize or improve strength IVIG in patients with MG, however, there is no current published study evaluating different administration routes of immunoglobulin (IVIG and SCIG) in patients with MG over a longer 6 month follow-up period.

The current study aims to be the first to evaluate 20% Cuvitru SCIG formulation in patients with neuromuscular conditions including MG. The study aim is to evaluate the safety and efficacy of 6 months of 20% SCIG Cuvitru treatment vs three months of 10% IVIG "pre-treatment" followed by 3 months of 20% SCIG Cuvitru treatment. The study will also be the first to use the myasthenia gravis impairment index (MGII) as primary outcome in conjunction with standard MG outcomes.

Connect with a study center

University Health Network
Toronto, Ontario M5G 2C4
Canada
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.